Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Colorcon
Merck

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

OLUMIANT Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Olumiant patents expire, and what generic alternatives are available?

Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-two patent family members in forty countries.

The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.

Summary for OLUMIANT
Drug patent expirations by year for OLUMIANT
Drug Prices for OLUMIANT

See drug prices for OLUMIANT

Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OLUMIANT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 1

See all OLUMIANT clinical trials

Pharmacology for OLUMIANT
Synonyms for OLUMIANT
(1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile
{1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
1187594-09-7
2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE
3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-
3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-
3JW
AB0035958
ABP001023
AC-27404
AJ-121247
AK143352
AKOS022186127
AKOS025401933
AM81232
AMMD00005
AOB87724
AX8261519
Baricitinib
Baricitinib (INCB28050 LY3009104)
Baricitinib (JAN/USAN/INN)
Baricitinib (LY3009104, INCB028050)
Baricitinib (LY3009104)
Baricitinib [USAN:INN]
baricitinib-ly3009104
BC600315
BCP04686
BCP0726000031
BCP9000380
BDBM50021656
C16H17N7O2S
CHEBI:95341
CHEMBL2105759
CS-0724
D10308
DB11817
DS-7641
DTXSID30152228
EX-A413
GTPL7792
HMS3651L17
HY-15315
INCB 028050
INCB 28050
INCB-028050
INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
INCB028050
ISP4442I3Y
J-503551
KS-0000044L
LY 3009104
LY-3009104
LY3009104
MFCD21608464
MLS006011247
NCGC00345839-01
NCGC00345839-14
Olumiant (TN)
PB27275
QCR-197
RL00725
S-7686
s2851
SB10845
SC-94301
SCHEMBL871150
SMR004703006
SW220096-1
UNII-ISP4442I3Y
XUZMWHLSFXCVMG-UHFFFAOYSA-N
Y0439
ZINC73069247

US Patents and Regulatory Information for OLUMIANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for OLUMIANT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2288610 122017000045 Germany   Start Trial PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610 315 50012-2017 Slovakia   Start Trial PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610 CA 2017 00032 Denmark   Start Trial PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
2288610 LUC00027 Luxembourg   Start Trial PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610 PA2017023,C2288610 Lithuania   Start Trial PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610 1790035-8 Sweden   Start Trial PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
2288610 PA2017023 Lithuania   Start Trial PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.